Search

Introduction: Atopic dermatitis (AD) is a heterogeneous, chronic, inflammatory skin disease with a non-negligible prevalence at present. Its pathogenesis is complex, but mainly characterized by constitutive T helper type 2 (Th2)-cell activation. Systemic therapies for moderate-to-severe AD can be associated with adverse events that encumber their satisfactory long-term use. Several drugs targeting relevant molecules in the immunopathogenesis of AD have been approved or are under clinical development for the treatment of moderate to severe AD. To elaborate this review, literature searches were performed in PubMed on 29 August 2020. Areas covered: This narrative literature review is focused on the pivotal role of IL-13 in the immunopathogenesis of AD and other skin diseases. Expert opinion: Dupilumab has demonstrated the central role of IL-13 and IL-4 in the pathogenesis of AD, asthma, and other diseases in the atopic spectrum. In addition, phase III randomized clinical trials (RCTs) evaluating specific blockade of IL-13 with tralokinumab for treatment of AD also demonstrated favorable results, and phase III RCT evaluating lebrikizumab are ongoing. The role of IL-13 in other skin diseases should be further investigated. [ABSTRACT FROM AUTHOR]

Allergic contact dermatitis, occupational allergic contact dermatitis, occupational dermatitis, patch test, isobornyl acrylate Two decades of occupational (meth)acrylate patch test results and focus on isobornyl acrylate. Keywords: allergic contact dermatitis; isobornyl acrylate; occupational allergic contact dermatitis; occupational dermatitis, patch test EN allergic contact dermatitis isobornyl acrylate occupational allergic contact dermatitis occupational dermatitis, patch test 352 354 3 04/07/21 20210501 NES 210501 Isobornyl acrylate (IBOA), is a photopolymerizable acrylate monomer that is used in various industrial products such as UV-cured coatings, sealants, glues, adhesives, paints, and inks.1,2 Here we report a case of occupational allergic contact dermatitis (ACD) to IBOA. [Extracted from the article]

Dear Editor, Pityriasis rubra pilaris (PRP) is a rare inflammatory dermatosis characterized by keratotic follicular papules coalescing into scaly red-orange plaques. The efficacy and rapid onset of action of brodalumab in PRP has already been observed in two other patients, who achieved complete response after 8 weeks.4,5 Treatment of type I PRP is often frustrating, and responses are generally slow and partial. Brodalumab might be the treatment of choice in type I PRP; as opposed to other therapeutic options, itch becomes quickly alleviated, and the efficacy of treatment can be assessed within 1 month. [Extracted from the article]